Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6063293 | 0.82 | NR1I2 (0.38) | NR1I2TDO2KIF11ALDH1A1HPGD | |
| SCHEMBL8715669 | 0.81 | NR1I2 (0.37) | NR1I2TDO2KIF11 | |
| SCHEMBL17962916 | 0.79 | NR1I2 (0.36) | NR1I2TDO2ALDH1A1HPGDALOX15 | |
| SCHEMBL8680470 | 0.75 | KIF11 (0.41) | NR1I2KIF11ALDH1A1HPGDTDP1 | |
| SCHEMBL3378773 | 0.74 | CA1 (0.39) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL1415048 | 0.73 | LMNA (0.34) | NR1I2ALDH1A1 | |
| SCHEMBL1793776 | 0.72 | CA1 (0.38) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL5754020 | 0.71 | — | — | |
| SCHEMBL28898073 | 0.71 | ALDH1A1 (0.46) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL4027510 | 0.70 | NR1I2 (0.35) | NR1I2KIF11ALDH1A1HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011041529-A2 | TRI-2-NAPHTHYLAMINES | ARIZONA BOARD OF REGENTS ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2011-04-07 | — | — | WO | disclosed |
| US-7267892-B2 | Electroluminescent devices having pendant naphthylanthracene-based polymers | EASTMAN KODAK COMPANY (US) | 2007-09-11 | — | — | US | disclosed |
| US-20070187673-A1 | ELECTROLUMINESCENT DEVICES HAVING PENDANT NAPHTHYLANTHRACENE-BASED POLYMERS | EASTMAN KODAK COMANY | 2007-08-16 | — | — | US | disclosed |
| EP-0963996-B9 | Transition metal compound, catalyst component and catalyst for olefin polymerization and process for the preparation of alpha-olefin polymer | JAPAN POLYCHEM CORP (JP) | 2006-09-06 | — | — | EP | disclosed |
| EP-0963996-B1 | Transition metal compound, catalyst component and catalyst for olefin polymerization and process for the preparation of alpha-olefin polymer | JAPAN POLYCHEM CORP (JP) | 2006-05-24 | — | — | EP | disclosed |
| US-6899963-B1 | Electroluminescent devices having pendant naphthylanthracene-based polymers | EASTMAN KODAK COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| US-6509426-B2 | Dichloro(1,1'-dimethylsilylenebis(2-methyl-4-(4-methoxyphenyl) -4H-azulenyl))zirconium, for example; can produce polyolefin with high molecular weight and high melting point for extrusion or injection moldability | JAPAN POLYCHEM CORPORATION (JP) | 2003-01-21 | — | — | US | disclosed |
| US-20010023296-A1 | Novel transition metal compound, catalyst component for olefin polymerization and process for the preparation of alpha-olefin polymer | JAPAN POLYCHEM CORPORATION (JP) | 2001-09-20 | — | — | US | disclosed |
| US-6218558-B1 | BRIDGED OXYGEN-, NITROGEN- OR SULFUR-CONTAINING METALLOCENE CATALYST CONTAINING AT LEAST CYCLOPENTADIENE RING FUSED TO A C7-10 RING | JAPAN POLYCHEM CORPORATION (JP) | 2001-04-17 | — | — | US | disclosed |
| EP-0963996-A2 | Novel transition metal compound, catalyst component for olefin polymerization and process for the preparation of alpha-olefin polymer | Japan Polychem Corporation (JP) | 1999-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010023296-A1 | Novel transition metal compound, catalyst component for olefin polymerization and process for the preparation of alpha-olefin polymer | OSTC, TCP1, COG1 | NR1I2 1685/4885TDO2 871/4885KIF11 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.